NCT05983549

Brief Summary

Feasibility and safety of targeting neutral vs liberal fluid balance in traumatic brain injured patients: a phase II randomized controlled trial

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2023

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 12, 2023

Completed
28 days until next milestone

First Posted

Study publicly available on registry

August 9, 2023

Completed
23 days until next milestone

Study Start

First participant enrolled

September 1, 2023

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

August 9, 2023

Status Verified

August 1, 2023

Enrollment Period

1.7 years

First QC Date

July 12, 2023

Last Update Submit

August 6, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Feasibility- rate of patients able to achieve neutral fluid balance( 0 +/- 500 ml) during the first week from ICU admission

    Ability to target and achieve a daily and total neutral fluid balance (0 +/- 500 ml) in the intervention group. In particular,testing the hypothesis of whether all pairwise differences between group means are the same in a design of repeated measures with 7 days points. We hypothesise a mean of 0 ml in the conservative group, a mean of 1000 ml in the liberal group and standard deviation in the population of 850 ml (500 ml in the conservative group and 1000 ml in the liberal group)

    7 days

Secondary Outcomes (2)

  • Safety to achieve neutral balance, i.e. the estimation of the difference of incidence of renal, pulmonary, cardiac complications between the two arms

    From date of randomization until the date of intensive care unit discharge or death assessed up to 6 months

  • Rates of patients who die and experience poor neurological outcome after 6 months from ICU admission

    6 months from ICU admission and enrolment

Study Arms (2)

Standard of care group

NO INTERVENTION

Patients will receive fluids according to clinical practice

Neutral balance

ACTIVE COMPARATOR

Patients will receive fluids aiming to a neutral balance

Procedure: fluid balance

Interventions

fluid balancePROCEDURE

patients will receive fluids with the aim to achieve a neutral balance

Neutral balance

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients with TBI (isolated or with extracranial injuries, with and without ICP monitoring)
  • Admitted to intensive care unit
  • Age \>18 years
  • Enrolment \<48h after ICU admission

You may not qualify if:

  • Enrolled in another clinical trial that is unapproved for co-enrolment
  • Pregnant or suspected pregnancy
  • Hemodynamic instability (HR \> 120 despite fluid resuscitation of at least 1 liter, and systolic blood pressure \< 90 mmHg) at the ICU admission requiring high dosage of norepinephrine (\> 0.5 mcg/kg/min) or inotropes (any dose)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Brain Injuries, TraumaticEdema

Interventions

Water-Electrolyte Balance

Condition Hierarchy (Ancestors)

Brain InjuriesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemWounds and InjuriesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

OsmoregulationBiochemical PhenomenaChemical PhenomenaMetabolismHomeostasisPhysiological Phenomena

Central Study Contacts

Chiara Robba, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Participant will be blinded in knowing the arm, outcome assessors will be not involved in the study
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Researcher

Study Record Dates

First Submitted

July 12, 2023

First Posted

August 9, 2023

Study Start

September 1, 2023

Primary Completion

May 1, 2025

Study Completion

September 1, 2025

Last Updated

August 9, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will share

IPD will be available

Shared Documents
STUDY PROTOCOL